Long‑term results of the HD0607 trial on interim PET‑adapted treatment of advanced‑stage Hodgkin lymphoma beyond 10 years of follow‑up
Long‑term follow‑up of the HD0607, a prospective phase‑2 multicentre trial, confirms that interim PET‑2–adapted therapy in advanced‑stage classic Hodgkin lymphoma provides durable disease control and a low cumulative incidence of second‑primary malignancies and cardiovascular events.
The study supplies the longest (>10 years) survival and late‑toxicity data for a PET‑adapted regimen in untreated advanced‑stage classic Hodgkin lymphoma, confirming that intensification only for PET‑positive patients yields sustained benefit without excessive long‑term morbidity.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
- Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
- Late cardiopulmonary morbidity in patients with Hodgkin lymphoma: a retrospective nationwide registry study
- Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma